NO985574L - FremgangsmÕter og preparater anvendelige for inhibering av angiogenese - Google Patents

FremgangsmÕter og preparater anvendelige for inhibering av angiogenese

Info

Publication number
NO985574L
NO985574L NO985574A NO985574A NO985574L NO 985574 L NO985574 L NO 985574L NO 985574 A NO985574 A NO 985574A NO 985574 A NO985574 A NO 985574A NO 985574 L NO985574 L NO 985574L
Authority
NO
Norway
Prior art keywords
inhibiting angiogenesis
methods
preparations useful
tissues
antagonists
Prior art date
Application number
NO985574A
Other languages
English (en)
Norwegian (no)
Other versions
NO985574D0 (no
Inventor
Peter Brooks
David A Cheresh
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of NO985574D0 publication Critical patent/NO985574D0/no
Publication of NO985574L publication Critical patent/NO985574L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/10—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO985574A 1996-05-31 1998-11-27 FremgangsmÕter og preparater anvendelige for inhibering av angiogenese NO985574L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1586996P 1996-05-31 1996-05-31
US1873396P 1996-05-31 1996-05-31
PCT/US1997/009158 WO1997045137A1 (en) 1996-05-31 1997-05-30 Methods and compositions useful for inhibition of angiogenesis

Publications (2)

Publication Number Publication Date
NO985574D0 NO985574D0 (no) 1998-11-27
NO985574L true NO985574L (no) 1999-02-01

Family

ID=26687899

Family Applications (2)

Application Number Title Priority Date Filing Date
NO985574A NO985574L (no) 1996-05-31 1998-11-27 FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
NO985575A NO985575L (no) 1996-05-31 1998-11-27 FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO985575A NO985575L (no) 1996-05-31 1998-11-27 FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese

Country Status (14)

Country Link
EP (2) EP0907661A4 (ko)
JP (1) JP2002515036A (ko)
KR (2) KR20000016301A (ko)
CN (1) CN1226254A (ko)
AT (1) ATE470450T1 (ko)
BR (1) BR9709514A (ko)
CA (2) CA2256588A1 (ko)
CZ (2) CZ383498A3 (ko)
DE (1) DE69739907D1 (ko)
DK (1) DK0951295T3 (ko)
HU (2) HUP9901628A3 (ko)
NO (2) NO985574L (ko)
PL (2) PL330240A1 (ko)
WO (2) WO1997045137A1 (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
WO2000003710A1 (en) 1998-07-14 2000-01-27 Pharmacia & Upjohn Company Oxazolidinones to treat eye infections
DE19842415A1 (de) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US6344484B1 (en) 1999-02-12 2002-02-05 3-Dimensional Pharmaceuticals, Inc. Tyrosine alkoxyguanidines as integrin inhibitors
SK287357B6 (sk) 1999-02-12 2010-08-09 The Scripps Research Institute Použitie antagonistu alfa v beta 3 na prípravu farmaceutickej kompozície na liečbu tumorových buniek a terapeutická kompozícia a súprava na liečenie tumoru alebo tumorových metastáz
UA71608C2 (en) * 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
US7037666B2 (en) * 2000-05-26 2006-05-02 Smithkline Beecham Corporation Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin αvβ3 and medical use thereof
CN1329167A (zh) * 2000-06-19 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人非整合蛋白－金属蛋白酶10.67和编码这种多肽的多核苷酸
US6486174B2 (en) 2000-08-07 2002-11-26 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
EP1381382B1 (en) 2000-11-01 2008-11-26 MERCK PATENT GmbH Methods and compositions for the treatment of diseases of the eye
JP4615826B2 (ja) 2001-01-29 2011-01-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用
CA2444821C (en) 2001-04-24 2012-07-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-angiogenic agents and tnfa
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US7019108B2 (en) 2001-06-01 2006-03-28 University Of Southern California Method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2
RU2311177C2 (ru) * 2001-08-01 2007-11-27 Мерк Патент Гмбх Ингибиторы интегрина для лечения заболевания глаз
DE10159453A1 (de) * 2001-12-04 2003-06-18 Merck Patent Gmbh Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease
GB0217017D0 (en) * 2002-07-23 2002-08-28 Bioacta Ltd Peptide 2
FR2856598B1 (fr) * 2003-06-25 2005-10-28 Inst Nat Sante Rech Med Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale
US7196061B2 (en) * 2003-09-10 2007-03-27 Wyeth Compounds that modulate neuronal growth and their uses
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
EP1862541A1 (en) * 2006-06-01 2007-12-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides derived from the hemopexin-like domain of metalloproteinase MMP-2
AU2008207095B2 (en) 2007-01-18 2013-08-29 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
US20110243927A1 (en) * 2007-08-24 2011-10-06 University Health Network Methods of inhibiting tumor growth using beta 5 integrin antagonists
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US20120130146A1 (en) 2009-05-25 2012-05-24 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
EP2504035B8 (en) * 2009-11-10 2019-06-05 Allegro Pharmaceuticals, LLC Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
WO2014163156A1 (ja) * 2013-04-04 2014-10-09 味の素株式会社 脱保護方法
WO2016040839A1 (en) * 2014-09-12 2016-03-17 Biogen Ma Inc. Humanized anti-alpha v beta 5 antibodies and uses thereof
CN111748041B (zh) * 2019-03-11 2021-09-14 中国科学院苏州纳米技术与纳米仿生研究所 微环境控释型功能化水凝胶、其制备方法及应用
CN116239704B (zh) * 2023-05-09 2023-07-14 北京青云智创科技有限公司 一种治疗新生血管性眼病的多肽及其制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
WO1997006791A1 (en) * 1995-08-14 1997-02-27 The Scripps Research Institute METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19538741A1 (de) * 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptidderivate

Also Published As

Publication number Publication date
HUP9901628A2 (hu) 1999-08-30
WO1997045137A1 (en) 1997-12-04
KR20000016301A (ko) 2000-03-25
PL330241A1 (en) 1999-05-10
DK0951295T3 (da) 2010-09-13
CA2256543C (en) 2010-12-07
CA2256543A1 (en) 1997-12-04
CA2256588A1 (en) 1997-12-04
PL330240A1 (en) 1999-05-10
WO1997045447A1 (en) 1997-12-04
HUP9901628A3 (en) 2002-11-28
WO1997045137A8 (en) 2001-02-01
CZ380098A3 (cs) 1999-05-12
NO985574D0 (no) 1998-11-27
CN1226254A (zh) 1999-08-18
HUP9902099A3 (en) 2001-10-29
NO985575D0 (no) 1998-11-27
DE69739907D1 (de) 2010-07-22
JP2002515036A (ja) 2002-05-21
BR9709514A (pt) 1999-08-10
CZ383498A3 (cs) 1999-05-12
EP0907661A4 (en) 2000-07-26
HUP9902099A2 (hu) 1999-09-28
ATE470450T1 (de) 2010-06-15
KR20000016302A (ko) 2000-03-25
EP0951295A1 (en) 1999-10-27
EP0951295B1 (en) 2010-06-09
EP0951295A4 (en) 2000-07-26
EP0907661A1 (en) 1999-04-14
NO985575L (no) 1999-02-01

Similar Documents

Publication Publication Date Title
NO985574L (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
NO954612D0 (no) Metoder og preparater for å behandle ooforektomiserte kvinner
NO20005190L (no) Terapeutiske angiogene faktorer og fremgangsmåter til anvendelse derav
NO994069L (no) Forbindelser for immunoterapi av prostatacancer og fremgangsmate for anvendelse derav
IL128003A0 (en) Therapeutic multispecific compounds comprised of anti-fcalpha receptor antibodies
IL147803A0 (en) 28-epirapalogs
NZ333399A (en) Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
TR199802423T2 (xx) Konsantre antikor terkibi.
DK0729951T3 (da) Naphthylforbindelser, mellemprodukter, præparater og fremgangsmåder
DK0928362T3 (da) Blokerende sammensætning til anvendelse i en underjordisk formation
ATE294595T1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DE69721810D1 (de) Konjugate zur behandlung von prostatakrebs
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
AU4396993A (en) Dipeptidyl peptidase-I, cloning it, and therapeutic agents containing inhibitors thereof
ZA200007211B (en) Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis.
DK1071433T3 (da) 2&#39;,2&#39;-difluornucleosider til immunosuppressiv behandling og kombinationspræparater
DE69933696D1 (de) Cytokinrezeptor-kette
DK0972782T3 (da) Monoklonalt antistof, der genkender oligosaccharidet N-glycolyleret galactose-glucose-sialinsyre i maligne tumorer, og præparater, der indeholder det
MXPA01010403A (es) Agentes quimiotacticos e inhibidores derivados de osteopontina y usos de los mismos.
NO980299D0 (no) Cytokinproduksjonsinhibitorer, preparater derav og deres anvendelse i medisin, samt fremgangsmåter for deres identifikasjon
HK1043058A1 (zh) 異環磷酰胺芥子類似物及其用途
DK0791591T3 (da) Benzothiophener, formuleringer indeholdende samme og fremgangsmåder til deres fremstilling

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application